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From the Editor’s Desk
Dear Readers,
LABRAD continues to enjoy a pan Pakistan reach
and also many hits on e commons(https://ecommons.
aku.edu/labrad/) by both national and international
readers. I shall assure all our readers that my team’s
consistent efforts will be aimed toward increasing
the visibility, impact, and the overall quality of
LABRAD. I hope our readers share a similar vision,
and we look forward to a productive, challenging
and successful 2019 ahead. In this issue you will find
two new sections added: ‘Polaroid’ and ‘Best from
the Past’. In the spirit of continuous improvement
feedback f rom you is very welcome.

In your hands you hold LABRAD’s second issue for
the year 2019. This issue is non-thematic with some
interesting reads like ‘Role of Serum Galactomannan
(GM) Assay in Diagnosing Invasive Aspergillosis,
‘Direct Immunofluorescence in Bullous Skin
Disorders’, ‘PET/CT Hybrid Imaging Technology’
and ‘Latest Trends in Clinical Laboratory Science
Technology’.
Happy reading.
Lena

Novel Molecular Technique for Identifying
Respiratory Tract Pathogens
Ms Ghazala Jabeen and Dr Mohammad Zeeshan
Microbiology

Today we are breathing in a gloomy global
environment which is contaminated with
poisonous gases, dirt and unsolicited microbes.
Our respiratory health is at stake and contributing
disease burden of different etiologies throughout
the globe.
Acute respiratory tract infections with spectrum
of etiological agents contribute significantly
in the morbidity and mortality of population
with different associated comorbid e.g.
children, adult with structural lung disease and
immunosuppressed masses. Laboratory diagnostic
curbs for respiratory infections further complicate
the consequence. This sometime compel physician
to use antibiotics when it could possibly be
avoided and hence promotes emerging antibiotic
resistance with heedless financial impact.
The causative agents of community associated
upper respiratory infections are typically selflimiting viral etiology. The spectrum of pathogens
involving lower respiratory tree include viral,
bacterial and fungal agents associate with

host’s risk factors. The advents of emerging
immunocompromise population in this era
necessitate the need of diagnostic accuracy for
respiratory pathogens to get better therapeutic
outcomes.
In a routine clinical microbiology laboratory
respiratory specimen culture and serological tests
are the main stay of diagnosis. These methods are
affective but limits it use because of specimen’s
quality, limited yield of causative agents, inability
to cultivate certain pathogens e.g. viruses, cell
membrane deficit bacteria and consumption of
diverse types of culture media for cultivation.
Non culture base diagnostic armamentarium e.g.
antigen and antibody based diagnostic methods has
been in use for long time for respiratory infectious
diseases, however, there diagnostic accuracies
are not always helpful. These diagnostic kits are
sometime strain specific, with the use of specific
diagnostic epitopes or antigens in kit and cross
reactivity due to antigenic sharing. Results might
also be deviate with the host’s immune response.
3
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Molecular technique by amplifying nucleic
acid of causative agents of respiratory tract
infection in a single specimen has improved
the diagnosis. The technology using multiplex
PCR coupled with fluidic or fixed microarrays
and provides a sensitive and comprehensive
approach for the diagnosis of respiratory tract
infections.
STEP 1: Sample preparation

Microbiology department has introduced FDA
approved multiplex PCR film array RP2 Panel
to detect the pathogens of upper respiratory tract
infections .The panel can detect 18 viruses and four
bacteria within turnaround time of one hour and
overall sensitivity and specificity of 95 percent and
99 percent respectively. This Panel system integrates
three simple steps

STEP 2: Amplification

1 - Insert pouch to loading station

STEP 3: Detection & analysis

2 - Inject hydration solution

4 - Insert pouch to loading station

3 - Inject sample

Fig. 1 Sample preparation and test performance steps

Table 1 Organisms detected by Bio Fire RP2 panel
Viruses
1.
2.
3.
4.
5.
6.
7.
8.
9.

Adenovirus
Coronavirus 229E
Coronavirus HKU1
Coronavirus OC43
Coronavirus NL63
Human Metapneumovirus
Human Rhinovirus/Enterovirus
Influenza A
Middle East Respiratory Syncial 		
CoronaVirus (Mers-CoV)

Bacteria
10.
11.
12.
13.
14.
15.
16.
17.
18.

Influenza A/H1
Influenza A/H1-2009
Influenza A/H3
Influenza B
Parainfluenza 1
Parainfluenza 2
Parainfluenza 3
Parainfluenza 4
RSV

In conclusion, this molecular testing methods will
significantly expanded our ability to diagnose
respiratory infections because of its rapidity,
sensitivity, and potential for the simultaneous
detection of 22 respiratory pathogens. Use of

4

1.
2.
3.
4.

Bordetella pertussis
Bordetella parapertussis
Chlamydophila pneumoniae
Mycoplasma pneumoniae

rapid and accurate diagnostic test increase the
ability of clinical decision making and results in
less antibiotics use help to promote the use of cost
effective treatment strategies.
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Role of Serum Galactomannan (GM) Assay in
Diagnosing Invasive Aspergillosis (IA)
Mr Syed Faheem Naqvi and Dr Mohammad Zeeshan
Microbiology

The estimated disease prevalence of invasive
aspergillosis (IA) ranges between 2.9 to 10 percent
in Pakistani population with different underlying
comorbids.
Definite diagnosis of IA needs multidisciplinary
approach which includes radiological imaging,
histopathology tissue biopsy and microbiological
culture. This is a perplexing task for a physician to get
all these tests timely and simultaneously especially in
low resource settings where the availability of all these
modalities is difficult as it require invasive procedures
to get appropriate specimen. These diagnostic
challenges in immunocompromised cadre lead to high
morbidity and mortality.
The advent of Aspergillus antigen assay –
Galactomannan (GM) contributes significantly in
the early diagnosis of IA. It is a soluble aspergillus
specific antigen that is released during the growth
phase of invasive aspergillosis. The assay is a
one-stage immunoen-zymatic sandwich microplate
serologic method.

Table 1 Galactomannan assay Interpreting Values
Specimen

Positive Assay
Index

Negative Assay
Index

Serum

Single ≥ 0.7 or two
consecutive
samples of > 0.5
Note: >1.0 is considered
a sign of therapeutic
failure

< 0.5

Bronchoalveolar
lavage

>1.0

< 0.5

Cerebrospinal
fluid

≥ 0.5

< 0.5

Physicians must correlate assay results in view with
underlying comorbid, clinical condition, microbiologic
and radiological evidence. Serial assays can be helpful
in case of high clinical suspicious.
One of the important limitations of this assay is the
false positive result due to various factors which
must keep in consideration when interpreting GM
results. Wrong interpretation can lead to injudicious
start of antifungal therapy. Numbers of factors which

Fig. 1 Principle and procedure of Galactomannan Assay

European Society for Clinical Microbiology and
Infectious Diseases (ESCMID), the European
Confederation of Medical Mycology (ECMM), the
European Respiratory Society (ERS) joint clinical
guidelines and infectious disease society of America
(IDSA) has endorsed GM in the diagnosis of IA.

are involved in the false positive GM assay are as
follows:
1. Cross-reactivity with therapeutic agent like:
		a. Plasmalyte.
		 b. Antimicrobial agents: amoxicillin,
5
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			amoxicillin-clavulanate and Piperacillin			tazobactam.
2. Cross reactivity with foods:
		 a. High GM content in pasta, rice, peas,
			 carrots, mushroom and spinach. Diet
			 contain high contents of these food can
			raise GM level.
3. Cross reactivity due to immunologic reaction:
		 a. In liver transplant recipients: Patients
			 with autoimmune liver disease were
			 more likely to have false-positive
			 tests than other liver transplant
			patients.
4. Cross reactivity with pathogens:
		 a. Non aspergillus fungal Species (e.g.
			Penicillium marneffei, Penicillium

			chrysogenum, Alternaria specie) and
			 bacterial species (e.g. In E.coli and
			Enterococcus faecalis bacteremia
There are causes of false negative results e.g.
prior or concomitant administration of antifungal
drugs, dependency on site of infection, growth and
specie type (low sensitivity for A.fumigatus) and
inappropriate testing, sampling and storage.
In conclusion, Galactomannan assay though a useful
diagnostic marker, but the result interpretation must
be performed very carefully and must correlate with
clinical conditions and rule out the causative factors
associated with false positive and false negative
result.

Factor VIII Inhibitor – A Diagnostic Approach
Dr Abdul Muqtadir Abbasi
Hematology & Transfusion Medicine

Introduction
Acquired inhibitors of coagulation are antibodies
that either inhibit the activity or increase
the clearance of a clotting factor. A common
clinical manifestation in affected patients is
a hemorrhagic diathesis. The most common
autoantibodies that affect clotting factor activity
and lead to a bleeding disorder are directed
against the activity of factor VIII, also called
acquired hemophilia A. Most of factor VIII
autoantibodies, have been IgG antibodies that do
not bind complement.
The reasons for the production of factor VIII
autoantibodies may involve the presence of certain
gene polymorphisms (eg, HLA, CTLA4) and/or
autoreactive CD4+ T lymphocytes.
An individual patient, either non-hemophilic or
hemophilic, can produce antibodies of different
IgG subclasses directed against different epitopes
on the factor VIII molecule. However production
of multiple antibodies is much more common in
patients with hemophilia. Most of these antibodies
bind to the C2 or, less often, the A2 domain on
factor VIII. Loss of the C2 domain, which binds to
the pro-coagulant phospholipid phosphatidylserine
6

on activated platelets and endothelial cells and
to von Willebrand factor, leads to reduced procoagulant activity.
The most common associated conditions were
malignancy, post-partum status, and autoimmune
disorders.
Clinical Features
Symptomatic patients often present with
large hematomas, extensive ecchymoses or
severe mucosal bleeding, including epistaxis,
gastrointestinal bleeding, and gross hematuria.
Spontaneous hemarthroses, which are common
in hereditary factor VIII deficiency, are unusual
in those with acquired disease. Bleeding is often
severe, constituting a medical emergency.
Diagnosis
The sudden presence of large hematomas or
extensive ecchymoses in an elderly individual
without significant trauma or known bleeding
disorder should always raise the clinical
suspicion of an acquired factor VIII inhibitor.
Following tests are required to accurately reach
the diagnosis.
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Coagulation Tests
Factor VIII inhibitors are characterized by a
prolonged activated partial thromboplastin time
(aPTT) and a normal prothrombin time (PT). The
differential diagnosis in this scenario includes

deficiencies of factors XI, IX or VIII, von Willebrand
disease, inhibitors of these factors, and the use of
heparin (Table 1). A prolonged aPTT is also seen in
the antiphospholipid antibody syndrome, but these
patients typically present with thrombosis rather than
bleeding episodes.

Table 1 – Causes of isolated prolonged aPTT
PT

APTT

Normal

Prolonged

Inherited
Deficiency of factor VIII, IX, or XI
Deficiency of factor XII, prekallikrein, or HMW kininogen (not associated with a bleeding diathesis)
von Willebrand disease (variable)
Acquired
Heparin, dabigatran, argatroban, direct factor Xa inhibitors (variable)
Acquired inhibitor of factor VIII, IX, XI, or XII
Acquired von Willebrand syndrome
Lupus anticoagulant (more likely to be associated with thrombosis than bleeding)

A reasonable first step is to exclude the use of
heparin as a cause of the patient’s bleeding and/or
prolongation of the aPTT. Also review the patient’s
medications.
The simplest approach is to redraw a blood sample
using an uncontaminated peripheral vein. If the
repeat aPTT is normal, the original sample was
probably contaminated with heparin. Then perform
a thrombin time and a reptilase time. Heparin is
present if the thrombin time is prolonged and the
reptilase time is normal.
Inhibitor screen (mixing test) — The initial
diagnostic test for a factor VIII inhibitor is the
mixing test or inhibitor screen. In this assay, varying
amounts of patient plasma and pooled normal plasma
are mixed and the aPTT measured. After mixing,
measurement of the aPTT should be performed not
only immediately but also after incubation at 37ºC
for one to two hours. The second measurement
is necessary to detect factor VIII inhibitors with
slow reaction kinetics. Correction of the prolonged
aPTT suggests a factor deficiency or VWD, while
persistent prolongation of the aPTT indicates

the presence of an inhibitor. The mixing test will
establish whether an inhibitor is present but will not
identify the inhibitor’s specificity.
The next step is adding a source of phospholipid to
the mixed plasma. Correction of the aPTT suggests
the presence of antiphospholipid antibodies. If
the aPTT does not correct, the Bethesda assay is
performed. The Bethesda assay both establishes
the diagnosis of a factor VIII inhibitor and
quantifies the antibody titer. By standardizing the
strength of factor VIII inhibitors, this assay also
permits comparison between different treatment
regimens.
Bethesda assay — In the Bethesda assay, serial
dilutions of patient plasma are incubated with pooled
normal plasma at 37ºC for two hours; factor VIII
activity is then measured using a clotting assay as
one would in a patient with hereditary factor VIII
deficiency. The reciprocal dilution of patient plasma
that results in 50 percent factor VIII activity is
defined as one Bethesda unit (BU). The stronger the
inhibitor, the greater the dilution required to allow
for factor VIII activity.

7
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PET/CT Hybrid Imaging Technology at Aga
Khan University Hospital
Professor Maseeh uz Zaman
Radiology

PET/CT is the cutting edge
hybrid imaging (fused)
technology of this century
and has become a standard of
care in many cancers. AKU
in pursuance of its vision
to deliver quality care to its
valued patients has stepped
into PET/CT arena with
an unprecedented donors’
support. For imaging tumour
within body, a radiolabelled
glucose (FDG) produce by
a cyclotron is required and
a reliable and sustainable
supply is mandatory to run
PET/CT scanner. Keeping in
view of unavoidable and not
uncommon frequent interrupted FDG supply to other
user in Karachi, AKU wisely decided to acquire a
cyclotron as well to ensure a reliable and sustainable
supply of FDG.
AKU selected the state of the art PET/CT scanner
(Celesteion®) which was launched in 2014 and
the first in this part of world. We selected this
machine for its best imaging and patient’s friendly
specifications as compared to others. For FDG
supply, AKU selected a cyclotron of USA make
(ABT, Dose on Demand®) having the smallest foot
print and need one-two operators to run this fully
automated highly sensitive but complicated unit.
This ABT cyclotron in each run (90-120 minutes/
run) produces FDG for three-four patients. However,
compared to conventional large foot-print cyclotron,
this Dose-On-Demand cyclotron cannot be used to
supply FDG to users outside AKU.
We start our work at 7.0 am in morning by starting
the ABT cyclotron to ensure to have first production
of FDG around 9.0 am and patients are scheduled
from 8.30 am onward. Patients are advised to come
with four hours fasting to ensure their fasting glucose
level < 200 mg/dl to avoid rescheduling.
After FDG injection, patients are advised to lie
8

comfortably and not vocalize to ensure good uptake
of FDG by tumour. After about 50 minute, patient is
move to PET/CT scanner which takes 15 minute to
acquire images from head to mid-thigh. Once images
are acquired, these are reviewed for adequacy and
patient is released with pertinent post-procedural
instructions.
We do PET/CT on daily basis (05working day/
week) and on average 8-12 patients/day. However,
sometime number goes below that figure due to
inadequate preparation (most common reason is
fasting blood glucose >200 mg/dl). PET/CT suite is
also being utilized very efficiently for CT Treatment
Planning (CTP) of radiotherapy patients. Around 4-5
patients of CTP are done on alternate days (two days)
and two-three on patients PET/CT days as well (03
days). AKUH is the only facility in Pakistan which is
using FDG PET/CT imaging for treatment planning
of tumour (Image Guided Radiation Therapy, FDG
PET/CT based IGRT).
So far we have done 4353 patients from 18th
December 2015 till 30th April 2019.
Graph is attached below.
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PET/CT images are reviewed and reported very
diligently by a team of a senior Nuclear Medicine
and Radiologist. Presently we have two Nuclear
Medicine Consultants and six Radiologists team who
are involved in reporting PET/CT examinations.

To run the PET/CT and cyclotron facilities
parallel daily, we have an efficient team of four
technologists. This is to mention that PET/CT
and Cyclotron team of AKU is the smallest one as
compared to others PET/CT facilities and this is due
to a fully automated cyclotron and state of the art
PET/CT scanner.
Recently we have also embarked upon into telereporting of PET/CT studies being sent to our
PET/CT section from other countries. Due to
an excellent coordinated efforts of our IT team,
technologists and reporting physicians, we have
been maintaining a reporting turn-around time of
100 percent (within 24 hour).

Diagnostic Tests for Von Willebrand Disease
Dr Qadeer Ahmed
Hematology & Transfusion Medicine

Von Willibrand disease (VWD) is the most common
inherited mucocutaneous bleeding disorder resulting
from deficiency or defective plasma von willibrand
factor. Von willibrand factor plays important role
in primary and secondry hemostasis. It binds to
collagen in exposed endothelium that enables it to
adhere to platelets at the site of blood vessel demage
through binding with Gp1b. It also carries factor VIII
in plasma, protecting it from premature proteolysis
and delivers it to site of blood vessel damage.
Types of Von Willibrand Disease
There are three major types of VWD
l
Type 1 is due to a quantitative reduction in
		 Von Willibrand factor (VWF) [both
		 concentration and activity are decreased].
l
Type 2 is due to dysfunctional VWF.
l
Type 3 is due to absent or severely reduced
		VWF.
Laboratory Testing
Baseline hemostasis assessment: VWD generally
will have a normal blood counts and a normal
platelet count, with the exception of those with
type 2B VWD, most of whom will have mild
thrombocytopenia and may have a normal or
prolonged activated partial thromboplastin time

(aPTT), depending on the degree of reduction of
the factor VIII level. The prothrombin time (PT) is
normal in VWD.
VWD screening tests: For initial testing for VWD,
there are three screening tests that assess the quantity
and function of von Willebrand factor (VWF).
VWF antigen (VWF:Ag) – Quantitative
measurement of VWF protein level: Plasma
VWF:Ag measures the quantity of VWF protein
in the plasma and most testing is now done using
an enzyme-linked immunosorbent assay (ELISA)based method on microtiter plates or by other
automated methods using latex beads coated with
antibodies to VWF and patient plasma as the source
of VWF.
A VWF:Ag level <30 percent (<30 international
units/dL) is consistent with VWD. Levels between
30-50 percent indicate “low VWF.” Levels >50
percent are considered normal.
VWF activity (VWF:Act) – Functional assays of
VWF binding to platelets or collagen.
VWF:RCo (ristocetin cofactor): VWF:RCo is an
assay that measures the ability of VWF to bind to
platelet membrane receptor GPIb. In the VWF:RCo
assay, ristocetin is added to patient plasma along
9
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with washed or formalin-fixed platelets, and the
amount of functional VWF in the plasma that causes
platelet agglutination is quantified using platelet
aggregometry or a manual (tilt tube) method.

A ratio of <0.5 to 0.7 is considered consistent with
type two VWD.

VWF:Ab – VWF:Ab is an automated assay that
measures binding of a specific monoclonal antibody
to the GPIb binding site on VWF.

The multimer proteins are separated by agarose
gel electrophoresis, and multimers of different
sizes are detected using anti-VWF reagents after
transfer to a membrane (eg, Western blotting with
chemiluminescence detection). Multimer distribution
can be quantified with densitometry of agarose gel
bands.

Collagen binding – VWF binding to collagen allows
VWF to be localized to the subendothelial matrix,
bringing bound platelets to the site of vascular
injury. Assays for collagen binding are performed
using ELISA plates coated with collagen (typically
collagen types I and III).
Factor VIII activity: Decreased factor VIII activity
may indicate reduced or dysfunctional VWF because
VWF acts as a carrier for factor VIII that protects
it from proteolysis, increasing its plasma half-life.
Significant reduction in VWF can decrease factor
VIII sufficiently to prolong the aPTT.
Other Screening Tests
Platelet function analyzer (PFA) assay:
A membrane that is coated with collagen , ADP, or
epinephrine and has a central aperture. The time to
closure of the aperture as the platelet plug forms is
measured. The closure time is dependent upon both
VWF and intrinsic platelet function.
Bleeding Time
Measures interaction of platelet with blood vessel
wall. BT is time consuming and highly operator
dependent procedure. BT may be abnormal in
individuals with VWD , but a normal BT does not
eliminate the possibility of VWD.
Ratio of VWF Activity to VWF Antigen
Ratio of VWF:Act to VWF:Ag as a means
of helping to identify patients with type two
VWD (dysfunctional VWF; qualitative defect).
Typically, the ratio of the ristocetin cofactor activity
(VWF:RCo) or the collagen binding activity
(VWF:CB) to VWF:Ag is used. A ratio >0.7 is
generally considered consistent with type 1 VWD,
with probable lower limits in the range of 0.5 to 0.7.

10

VWF Multimer Analysis

Ristocetin-Induced Platelet Aggregation (RIPA)
RIPA measures the affinity with which VWF binds to
the platelet receptor GPIb. The presence or absence
of platelet aggregation is noted at each concentration
of ristocetin. Platelet rich plasma (PRP) from
patients with normal VWF does not aggregate at
concentrations of ristocetin that are lower than
approximately 0.6 to 0.8 mg/mL, but PRP from
patients with type 2B VWD will usually aggregate at
concentrations of ristocetin of 0.4 to 0.5 mg/mL.
Specialized Tests for VWD
VWF propeptide (VWF:PP) — The VWF:PP
is a protein sequence that is part of VWF when
it is initially synthesized; it is cleaved during the
release of VWF into the circulation, and it circulates
independently with its own half-life. As such, it is
a marker for the amount of newly synthesized and
released VWF. When VWF has a short half-life (as
in rapid clearance of VWF due to any cause), the
ratio of VWF:PP to VWF:Ag is elevated (ratio >3).
VWF:PP to VWF:Ag ratio is helpful in the diagnosis
of acquired von Willebrand syndrome.
VWF binding to factor VIII (VWF:FVIIIB) —
VWF mutations in the binding site for factor VIII
cause decreased binding of VWF to factor VIII
leading to low levels of factor VIII and the diagnosis
of VWD type 2N. The binding assay is usually
performed in an ELISA format, using the patient’s
plasma VWF to coat the wells and recombinant
factor VIII as the added binding protein. The ability
of the patient’s plasma VWF to bind factor VIII is
compared with that of a normal plasma pool.
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Iron Deficiency Anemia
Dr Seher Rasheed
Haematology & Transfusion Medicine

Iron deficiency anemia arises when the balance of
iron intake, iron stores, and the body’s loss of iron
is disturbed, leading to insufficient production of
erythrocytes. The WHO defines anaemia in adults
as a haemoglobin less than 13.0 mg/L in males and
less than 12.0 mg/L in females. In the developed
world, this disease is easily identified and treated,
but frequently overlooked by physicians. In contrast,
it is a health problem that affects major portions of
the population in underdeveloped countries. In 2010,
global anemia prevalence was 32.9 percent (i.e.,
more than 2.2 billion people were affected); iron
deficiency was the most common cause.

the rate of erythropoiesis and the state of body iron
stores.
Iron Homeostatis

Schematic representation of the pathways involved
in iron (Fe) homeostasis. The amount of iron passing
from mucosal cells into the body is determined by
Physiological Conditions and Pathological Disorders Associated With Iron Deficiency Anemia
PHYSIOLOGICAL
l
l
l
l

Infancy
Adolescence in girls
Pregnancy
Regular blood donation

PATHOLOGICAL
Blood loss
l
Digestive tract: colonic carcinoma, gastric
		
carcinoma, inflammatory bowel
l
Diseases, ulcers, angiodysplasia, parasites
l
Gynecological loss
l
Surgery
l
Hematuria, epistaxis, hemoptysis
l
Hemodialysis
l
Non-steroidal anti-inflammatory drugs, 		
		aspirin

Iron deficiency anemia associated with
anemia of chronic disease
l
Chronic heart failure
l
Cancers
l
Chronic kidney disease
l
Rheumatoid arthritis
l
Obesity
l
Inflammatory bowel diseases

Malabsorption
l
Coeliac disease
l
Gastrectomy
l
Helicobacter pylori
l
Gut resection, atrophic gastritis, bypass
		
gastric surgery, bacterial overgrowth
l
Interaction with food elements: tea, coffee,
		
calcium, flavonoids, oxalates, phytates

Genetic disorders
l
Iron-refractory iron deficiency
		anemia
l
Others (divalent metal
		
transporter 1 deficiency
		
anemia, Fanconi anemia,
		
pyruvate kinase deficiency, etc.)

Clinical Features
Iron deficiency anemia signs and symptoms may
include:
 Extreme fatigue
 Weakness
 Pale skin
 Chest pain, fast heartbeat or shortness of
		breath

 Headache, dizziness or lightheadedness
 Cold hands and feet
 Inflammation or soreness of your tongue
		(Glossitis)
 Brittle nails, spoon shaped nails (Koilonychia)
 Unusual cravings for non-nutritive
		 substances, such as ice, dirt or starch (Pica)
 Poor appetite, especially in infants and
		 children with iron deficiency anemia
11
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Complications
Mild iron deficiency anemia usually doesn’t cause
complications. However, left untreated, iron deficiency anemia can become severe and lead to health
problems, including the following:
Heart problems: Iron deficiency anemia may lead to
a rapid or irregular heartbeat. Your heart must pump
more blood to compensate for the lack of oxygen
carried in your blood when you’re anemic. This can
lead to an enlarged heart or heart failure.
Problems during pregnancy: In pregnant women,
severe iron deficiency anemia has been linked to
premature births and low birth weight babies. But
the condition is preventable in pregnant women who
receive iron supplements as part of their prenatal care.
Growth problems: In infants and children, severe
iron deficiency can lead to anemia as well as
delayed growth and development. Additionally, iron
deficiency anemia is associated with an increased
susceptibility to infections
Laboratory Diagnosis of Iron Deficiency Anemia
Typically, the evaluation of the cause of anemia
includes a complete blood cell count, peripheral
smear, reticulocyte count, and serum iron indices.
The severity of anemia is based on the patient’s
hemoglobin/hematocrit level.
Red Cell Indices and Blood Film
Even before anemia occurs, the red cell indices fall
and they fall progressively as the anaemia becomes
more severe. The mean corpuscular volume is the
measure of the average red blood cell volume and mean
corpuscular hemoglobin concentration is the measure
of the concentration of hemoglobin in a given volume
of packed red blood cells. The normal reference ranges
for mean corpuscular volume is 80–100 fL and mean
corpuscular hemoglobin concentration is 32.0–36.0 g/l.
The patient’s cells are said to be microcytic and
hypochromic, respectively, when these values are less
than the normal reference range.
Microcytic hypochromic anemia of iron deficiency
(peripheral blood smear)

The blood film shows hypochromic, microcytic
cells with occasional target cells and pencil‐shaped
poikilocytes. The reticulocyte count is low in relation
to the degree of anemia. The platelet count is often
moderately raised in iron deficiency.
Laboratory Diagnosis of Iron Deficiency Anemia
MCV/MCH

Reduced in relation to
severity of anemia

Serum iron

Reduced

TIBC

Raised

Serum ferritin

Reduced

Bone marrow iron
stores

Absent

Erythroblast iron

Absent

Hemoglobin
electrophoresis

Normal

MCH, mean corpuscular hemoglobin;
MCV, mean corpuscular volume; TIBC,
total iron‐binding capacity
Serum Iron and Total Iron‐Binding Capacity
The serum iron falls and total iron‐binding capacity
(TIBC) rises so that the TIBC is less than 20 percent
saturated. This contrasts both with the anaemia of
chronic disorders, when the serum iron and the TIBC
are both reduced, and with other hypochromic anemia where the serum iron is normal or even raised.
Serum Ferritin
A small fraction of body ferritin circulates in the
serum, the concentration being related to tissue,
particularly reticuloendothelial, iron stores. The
normal range in men is higher than in women. In iron
deficiency anaemia the serum ferritin is very low
while a raised serum ferritin indicates iron overload
or excess release of ferritin from damaged tissues or
an acute phase response (e.g. in inflammation). The
serum ferritin is normal or raised in the anaemia of
chronic disorders.
Bone Marrow Iron
Bone marrow examination is not essential to assess
iron stores except in complicated cases. In iron
deficiency anaemia there is a complete absence of
iron from stores (macrophages) and from developing
erythroblasts. The erythroblasts are small and have a
ragged cytoplasm.

12
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Usually, a ferritin test is used to
evaluate the amount of iron reserve
in the body and to help diagnose iron
deficiency anemia. However, the
ferritin level can be elevated when
an individual has inflammation or a
chronic disease, such as autoimmune
disorders or some cancers. In
these conditions, the ferritin test
is not useful and a test for soluble
transferrin receptors may be ordered.
(a)

(b)

Bone marrow iron assessed by Perls’ stain. (a)
Normal iron stores indicated by blue staining in
the macrophages. Inset: normal siderotic granule in
erythroblast. (b) Absence of blue staining (absence
of haemosiderin) in iron deficiency. Inset: absence of
siderotic granules in erythroblasts.
Soluble Transferrin Receptor
Soluble transferrin receptors are proteins found
in blood that can be elevated with iron deficiency.
This test measures the amount of soluble transferrin
receptors to help detect and evaluate iron deficiency
and distinguish it from anemia caused by chronic
illness or inflammation.
Transferrin is the main protein in the blood that binds
to iron and carries it to tissues and cells throughout
the body. About 80 percent of iron is transported to
the bone marrow, where it is incorporated into the
hemoglobin in red blood cells (RBCs), and the rest
is stored in other cells and tissues as ferritin and
hemosiderin.

Reticulocyte Haemoglobin Equivalent
Measuring the haemoglobin content of reticulocytes,
also known as RET-He or reticulocyte haemoglobin
equivalent, is a way of diagnosing and monitoring
iron deficiency anemia. Measuring the haemoglobin
content of the reticulocytes as a direct assessment
of the iron actually used for the biosynthesis of
haemoglobin can indicate whether there is enough
iron available for erythropoiesis.
The clinical utility of the Ret-He parameter has been
proven and it is now an established parameter in
advanced haematological analysis. Considered the
most sensitive indicator of current iron availability
for erythropoiesis
Differential Diagnosis
IDA is classically described as a microcytic anemia.
The differential diagnosis for microcytic anemia
includes iron deficiency, thalassemia, sideroblastic
anemias, some types of anemia of chronic disease,
and lead poisoning (rare in adults).

Sweat Testing for Diagnosis of Cystic Fibrosis
Dr Tayyaba Hassan and Ms Humera Asif
Chemical Pathology

Cystic fibrosis (CF) is a common potentially life
limiting genetic disease, affecting 0.737 - 1/10,000
live births. It is an autosomal recessive disorder
causing multisystem disease with viscous secretions
in the lungs, bronchi, biliary tract, intestines
and pancreas. In the lungs, the mucus clogs the
airway and traps germs like bacteria, leading to
infections, inflammation, respiratory failure and
other complications. It is caused by mutations in the

cystic fibrosis transmembrane conductance regulator
(CFTR) gene that encodes the CFTR protein, an
ion channel protein which transports chloride ions
across the membranes of cells that line airways,
glands and digestive tract. Outcome of a CF patient
depends on timely and accurate diagnosis. According
to the Cystic Fibrosis Foundation consensus report,
the criteria for the diagnosis of CF includes CFTR
protein abnormality with biological evidence of
13
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channel dysfunction (i.e., abnormal sweat chloride
concentration) or identification of a CF diseasecausing mutation in CFTR gene).
Diagnosing cystic fibrosis is a multistep process, and
should include a newborn screening, followed by
confirmatory genetic testing. To evaluate if an infant
has cystic fibrosis, sweat test can also be conducted
if the infant is atleast two weeks old as the children
with cystic fibrosis clearly show elevated electrolyte
concentrations in their sweat compared with the
children unaffected by the disease. At Aga Khan
clinical laboratory, a screening test for CF sweat
conductivity test is available.

is used for sweat testing and results interpreted by
continuous –flow analysis on the analyzer display.
Results considered abnormal if values >50mmol/L
(equivalent NACL).
Test should be conducted at room temperature (2225 °C) with a relative humidity of approximately
60 Percent. The electrical conductivity of sweat is
a function of total ionized particles in the sweat i.e.
sodium potassium, small amount of ammonium and
chloride. In cystic fibrosis as the CFTR chloride
channel is defective so chloride cannot be absorbed
properly into sweat duct cells, resulting in high
concentration of chloride in sweat.

Sweat Test Procedure

Limitations

Prior to the sweat testing, detailed history of the
patient is taken on a structured questionnaire and
hydration status of the patient is assessed. For sweat
collection, an area of skin on the arm free of cuts,
rashes and inflammation is selected. Pilocarpine
gel, a medicine that makes the sweat glands
produce sweat, is applied on the flexor surface of
the forearm after washing with water and patted
dry. The sweat analysis system (Nanoduct, Wescor
Inc., Logan, Utah, Biomedical products Division )

Sweat chloride conductivity test can give false
positive results and is cumbersome to perform. And
since the chloride concentration in sweat is directly
related to sweat production rate so chances of false
negative results increases with less sweat production.
According to the data collected, failure rate of sweat
production is high in our population (20-40 percent,
while <5 percent is recommendation of regulatory
bodies). So it is advisable that patients coming for
sweat testing are well hydrated.

Flow Cytometric Identification of Abnormal
B-Cells
Dr Muhammad Shariq Shaikh and Dr Arsalan Ahmed
Haematology & Histopathology

B-cell lymphoproliferative disorders are clonal
expansion of the various stages of B-lymphocytes
in bone marrow, blood or other tissues. Mature
B-cell neoplasms comprise over 90 percent of
lymphoid neoplasms worldwide. The World Health
Organization (WHO) classification of lymphoid
neoplasms suggests that distinct clinical entities can
be defined based on morphology, immunophenotype,
genetic abnormalities and clinical features. Flow
cytometric analysis not only assists in diagnosis
and classification but also provides prognostic
information for appropriate treatment of patients
with chronic lymphoproliferative disorders.
Amongst various abnormalities that are found in the
evaluation for B-cell malignancies, the most useful
14

feature of B-cell neoplasia is light chain restriction
or monophasic staining with kappa and lambda.
In normal B-cell, surface staining for light chains
is heterogeneous; that is both kappa and lambda
expressing B-cells are identified. The normal kappa
to lambda ratio is approximately 2:1. In cases where
predominant B-cell population is malignant, light
chain restriction may be easily demonstrated with
flow cytometry.
Frequently, monoclonal B-cells are admixed with
polyclonal population. In such cases, differential
expression of normal B-cell antigens in benign and
malignant cells is useful. By examining B-cells for
populations with abnormal levels of CD19, CD20,
or CD22 expression, one can isolate an abnormal
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B-Cell population and demonstrate monoclonality.
For instance, CD20 in chronic lymphocytic leukemia
is dimly expressed whereas CD20, CD22 and CD11c
are bright positive in Hairy Cell Leukemia. Absence
of normal antigens and aberrant expression of other
lineage markers (such as T-cells or myeloid antigens)
are also useful features of abnormal B-cells. Absence
of normal B-cell antigens provide some insight into
prognosis as this features is frequently observed in
High grade B-cell lymphomas.

lymph nodes with florid hyperplasia.
Co-expression of certain markers can readily
be demonstrated by designing appropriate
antibody panels that can help establishing the
monoclonality. Multiparametric analysis of CD5
in Chronic Lymphocytic Leukemia/Mantle Cell
Lymphoma and CD10 in follicular lymphoma
are prime examples which are routinely used for
sub-classification of B-cell lymphoproliferative
disorders.

Specimen site should also be considered while
dealing with B-cell malignancies. The presence of
significant number of CD10+ (Pre B-cells) is normal
in bone marrow however their presence in peripheral
blood is highly atypical. Expression of CD5, CD10
and CD23 is typically low in benign lymph nodes but
CD10 positive cells can readily be present in benign

Lastly, light scatter characteristics also provide
important information about cells in question.
Abnormally high forward light scatter is observed
in large cell lymphoma and high side scatter is seen
in hairy cell leukemia. Therefore, proper gating
strategies are of utmost importance to avoid missing
a malignant B-cell population.

Direct Immunofluorescence in Bullous Skin
Disorders
Dr Saira Fatima
Histopathology

The vesiculobullous disorders of skin are divergent
group of disorders manifested as fluid filled blisters
either within or below the epidermis & mucosal
surfaces. The underlying mechanism of vesicle
formation, level of split and dermal inflammatory
infiltrate varies in these diseases despite a clinical
overlapping picture. An accurate diagnosis is
mandatory as some of them may be life-threatening
and therefore correct characterization is of utmost
importance. The light microscopic examination
alone may be inadequate in many scenarios either
due to early stage, eroded epidermis and epithelial
regeneration. Direct immunofluorescence (DIF) is
extremely valuable in these cases to reach a definite
diagnosis.
DIF is technique in which deposits of immune
reactants can be seen in tissue by using antigenantibody reaction. The antigen is detected in fresh
skin tissue by using fluorescein isothynate (FITC)labeled antibody. The sections are then examined
under epifluroscence microscopy. The fresh vesicle
is biopsied taking two third of the vesicle and one
third of intact peri-lesional skin. If a sample is
being obtained in the same laboratory then it can be
immediately placed in embedding medium Tissue-

Tek O.C.T compound. If specimen needs to be
transported to the testing lab, then it is preferable
to place the sample in Michel transport medium,
which is reported to preserve the immunoreactivity
for longer time. Zeus solution can be an alternate to
Michel medium in case of non-availability. Another
method to send the specimen may be to place the
specimen on saline-soaked gauze, then in a plastic
bag which in turn will be put in a jar containing
ice and delivered to the lab within two hours of the
biopsy.
DIF is not only an adjunct tool in bullous disorders
but also help in the diagnosis of connective tissue
diseases & vacuities. However, guidelines for
DIF sampling need to be followed to avoid a false
negative report. The following are the general facts.
• Blistering disorders –
			
–
				
				
				
			
–
				

peri-lesional skin
Peri-lesional skin =
normal skin
immediately adjacent
to a lesion
Immune deposits are
degraded in inflamed or
15
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				 blistered skin which
				 can result in false
				 negative DIF
			
– avoid an ulcer or an
				 area where the
				 epidermis is disrupted
			
– Avoid active lesions
• Connective tissue diseases – lesional skin

Disease

16

Location of Immune deposits

			
–
				
				
				
				
			
–
				
• Vasculitis
–

Predominant
Sensitivity
Immunoreactant

For SLE lupus band
test x 2 biopsies of
lesional and non-sun
exposed normal skin
(buttock or inner thigh)
Avoid old lesions and
facial lesions
lesional skin
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A Short Review of Recent Changes in WHO
Classification and TNM Staging for Testicular
Neoplasms in the American Joint Committee on
Cancer in Eighth Edition of Cancer Staging Manual
Dr Ummiya Tahir and Dr Sidra Arshad
Histopathology

WHO Classification
The latest fourth edition of WHO classification of
the urinary system and male genital organs, referred
as blue book was published after more than a decade
in 2016 and incorporated certain significant changes
in classification of testicular tumours. Both the
CAP and ICCR documents incorporate the World
Health Organization (WHO) 2016 Classification of
Testicular Tumours.
l

		
		
		

In 2016 WHO classification, Germ Cell 		
Tumours (GCTs) are broadly categorized
on the basis of their association with Germ
Cell Neoplasia in Situ (GCNIS)

 Those related to NIS; associated
				 with isochromosome 12p(i12p)
 Those not related to GCNIS; not
				 associated with i12p, found in
				 children and usually have a benign
				or indolent behavior
ASSOCIATED to GCNIS
l
Pure seminoma
l
Non-seminomatous (NSGCT) tumours
		 Embryonal carcinoma
		 Yolk sac tumour (YST) of 			
			postpubertal type
		 Teratoma of postpubertal type (including
			 teratoma with somatic type malignancy),
l
Trophoblastic tumours
Choriocarcinoma,
Mixed NSGCTs and regressed GCTs.
NOT ASSOCIATED WITH GCNIS
l
Spermatocytic tumour ,
l
Teratomas of prepubertal type
l
Yolk Sac Tumor of prepubertal type
Notable changes include
A-Germ Cell Neoplasia in Situ which replaced the

terms intratubular germ cell neoplasia, unclassified
type (IGCNU), carcinoma in situ (CIS) and testicular
intraepithelial neoplasia (TIN)
B-Teratomas classified as
1. Prepubertal.
2. Postpubertal.
C- Spermatocytic Tumor: Previously known as
spermatocytic seminoma is not recommended term
and is not a subtype of classical seminoma.
D-Classification of Sex-cord Stromal tumors
1.Pure Sertoli cell tumours (SCT)
2.Specific SCT variants
3.Pure Leydig cell tumours
4.Adult and juvenile type granulosa cell tumors
5.Tumours in the fibroma-thecoma group
6.Mixed and unclassified SCST’s
Formerly there were several SCT variants including
SCT not otherwise specified (NOS),
Sclerosing SCT,
Lipid-rich SCT and
Large cell calcifying SCT.
Sclerosing SCT has been collapsed into the SCT
NOS category in the 2016 WHO classification.
The term lipid-rich SCT has also been dropped
from the updated nomenclature for SCT’s.
Lipid-rich cells with signetring- like morphology
have been identified in variable proportions in SCT
NOS, with/without sclerotic stroma.
Large cell calcifying SCT persists in the 2016 WHO
classification.
Intratubular large-cell hyalinizing Sertoli cell
neoplasia is being added as a separate entity within
the SCT category.
TNM Staging
Cancer staging is a vital component of a pathological
report and has serious implications on patient
management. The primary purpose of TNM system
17
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is to provide an anatomic-based classification to
adequately depict cancer prognosis and treatment.

The following is the New TNM staging according to
the eighth edition of cancer staging manual.

PRIMARY TUMOR (pT)
pTX
pT0
pTis
pT1
pT1a
pT1b
pT2

pT3
pT4

Primary tumor cannot be assessed
No evidence of primary tumor
Germ cell neoplasia in situ
Tumor limited to testis (including rete testis invasion) without lymphovascular invasion
Tumor smaller than 3 cm in size (applies only to pure seminoma)
Tumor 3 cm or larger in size (applies only to pure seminoma)
Tumor limited to testis (including rete testis invasion) with lymphovascular invasion
OR
Tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer
covering the external surface of tunica albuginea with or without lymphovascular invasion
Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion
Tumor invades scrotum with or without lymphovascular invasion

REGIONAL LYMPH NODES (pN)
Regional lymph nodes cannot be assessed
pNX
No regional lymph node metastasis
pN0
Metastasis with a lymph node mass 2 cm or smaller in greatest dimension and less than or equal to five
pN1
nodes positive, none larger than 2 cm in greatest dimension
Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension, or
pN2
more than five nodes positive none larger than 5 cm, or evidence of extranodal extension of tumor.
Metastasis with a lymph node mass larger than 5 cm in greatest dimension
pN3
DISTANT METASTASIS(pM)
pM1
Distant metastasis – now includes discontinuous involvement of the spermatic cord by tumor in vascular spaces that have
invaded in to spermatic cord soft tissue
pM1a
Non retroperitoneal nodal or pulmonary metastases
pM1b
Non pulmonary visceral metastases
l Text in red highlights changes introduced in the
		 recent AJCC manual, eighth edition
Reference: WHO classification of tumours of the urinary system and
male genital organs; fourth edition

PRACTICE POINTS
GNCIS is now the preferred term for precursor
lesions of GCTs. The absence of GNCIS in
parenchyma adjacent to an apparent GCT,
should prompt consideration of a diagnosis

18

such as a spermatocytic tumour or a SCST.
Other 2016 WHO changes include the
distinction between prepubertal and postpubertal
teratoma, the replacement of spermatocytic
seminoma with the term spermatocytic
tumour and the consolidation of previously
recognized variants of SCT within SCT, NOS.
pTNM AJCC 8th edition staging changes require
more attention to thorough sampling of the testicular
hilum, epididymis and spermatic cord.
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Radiology-Pathology Correlation; Orthopedic
Pathology
Dr Nasir Ud Din & Dr Dawar Khan
Histopathology and Radiology

A 26-year-old male presented to
an outside hospital orthopedic
OPD with a nine months history of
insidious onset pain, stiffness and
swelling around left knee. His knee
pain was progressively worsening,
aggravating by weight bearing
activity and restricting his day to
day activities. The swelling around
knee was progressively increasing
in size. There was no history of
trauma, constitutional symptoms or
other joint involvement. An x-ray AP
and Lateral view was taken which
showed soft tissue swelling with
extensive small nodular/punctate
calcification posteriorly. However
underlying bone appears intact but
exhibit mild degenerative changes.

A

B

Figure 1A & B. x-ray knee AP and lateral views

Patient underwent limited
synovectomy along with removal of
multiple variable size and shape friable white loose
bodies. Histological examination showed variable
size and shape lobules of cartilage along with the
synovial tissue. The chondrocytes in these lobules
showed clustering. The combined radiological
and histological findings were consistent with the
diagnosis of primary synovial chondromatosis (SC).

A

Discussion
Synovial chondromatosis is a benign monoarticular
disorder of unknown origin which is characterized
by metaplasia and proliferation of synovium into
multiple intra-articular cartilaginous loose bodies
which may calcify and ossify.

B

Figure. A & B. Low and high power examination of synovial chondromatosis. Lobules of chondrocytes are seen.
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It is classified under two main types:

most often multiple and of uniform size.

primary synovial chondromatosis: predominantly
monoarticular disorder of unknown etiology
secondary synovial chondromatosis: resulting
in intra-articular loose bodies from causes such
as trauma, osteoarthritis, rheumatoid arthritis and
neuropathic arthropathy.

Histologically, both primary and secondary SC
is composed of nodules of hyaline cartilage.
Calcification and ossification is seen in long
standing nodules. In primary SC, the chondrocytes
are organized in clusters within an abundant
chondroid matrix and may show moderate
cytological atypia and binucleation. Secondary SC
is often associated with degenerative changes of
the articular cartilage and bone. Cellularity is lower
than in primary SC.

The knee followed by the hip are the most commonly
involved sites. Extra-articular SC is most prevalent
in the tendon sheaths of the hand and feet. The age
range is wide but most patients present in the fourth or
fifth decades of life. Men are affected more frequently
(M:F ratio of 2:1 to 4:1). Secondary SC usually
arises in older patients. Patients usually present with
pain, swelling, and limitation of motion, which often
progresses slowly for several years. Joint effusions
are common as there is a restricted range of motion.
Radiological features of synovial chondromatosis
depend on the degree of ossification that has occurred.
When calcification is absent (one third of cases) plain
radiographs may be normal or reveal a non-specific
findings, e.g. soft-tissue mass surrounding the joint,
widening of the joint space, erosions of adjacent
bones, or early osteoarthritic changes.
When extensive ossification is present, then many
calcific joint bodies are present, either fully ossified,
or partly showing the ring and arc like calcifications
characteristic of chondroid calcifications. They are

Histologically, extra-articular SC may be
misdiagnosed as chondroma of soft parts, which
also primarily affects the hands and feet. Chondroma
of soft part, however typically presents as a
solitary mass in younger patients. Primary synovial
chondrosarcoma is extremely rare, and distinguished
from primary SC by significant atypia, mitosis and
underlying bone invasion.
Treatment and Prognosis
Treatment of synovial chondromatosis usually consists
of removal of the intra-articular bodies with or without
synovectomy, but local recurrence is not uncommon,
occurring in ~12.5 percent (range 3-23 percent)
of cases. Recurrences are treated by re-excision.
Malignant transformation into chondrosarcoma has
been reported but is extremely rare.

Fecal Elastase: A Marker For Exocrine
Pancreatic Function
Dr Faryal Husnain and Ms Saba Ijaz
Clinical Chemistry

Exocrine pancreatic insufficiency (EPI) is a
condition caused by reduced or inappropriate
secretion of pancreatic enzymes. EPI can result in
clinical and biochemical manifestations causing
reduced quality of life and in severe cases, even
life-threating complications. The pancreatic causes
of EPI includes, Cystic Fibrosis (the most common
cause), acute pancreatitis, tumours involving
the pancreas, resective pancreatic surgery and
Schwachman-Diamond Syndrome. While extrapancreatic causes include, Diabetes Mellitus,
Inflammatory bowel disease, gastric surgery, aging,
20

chronic and critical illness, infections like HIV and
tobacco exposure.
There are various laboratory tests available to
diagnose pancreatic insufficiency, called Pancreatic
Function Tests including fecal fat testing, fecal
elastase and pancreatic function test. The pancreatic
function test is considered the most sensitive test
for diagnosing EPI. It is an invasive procedure,
involving a tube insertion into small intestine to
collect pancreatic secretions and Cholecystikinin
and secretin are measured in it. This test however is
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cumbersome, invasive, time-consuming, costly and
also cannot detect response to pancreatic enzyme
replacement therapy. The fecal fat testing measures
the total fat in stool sample collected over a three
day period. This test is also inconvenient for most
of the aptienst because of three day stool collection
and has low specificity to diagnose EPI. That is why
fecal elastase is considered the test of choice. At
the Aga Khan Clinical Laboratory we have recently
started fecal elastase testing.
Pancreatic fecal elastase-1:
Fecal Elastase 1 is a proteolytic enzyme produced
by pancreatic acinar cells, which binds to bile
salts and passes through the gut with slight
degradation, the concentration of this enzyme
in the feces is five times higher than that in the
pancreatic juice. Therefore, it reflects the level
of pancreatic output and correlates also with the
output of other pancreatic enzymes such as lipase,

amylase, and trypsin. It has five isoforms (CELA1,
CELA2A, CELA2B, CELA3A, and CELA3B) of
these proteins, the biological specificity of which
is largely unknown. The available commercial
assay is an ELISA quantifying CELA2 and/or
CELA3 isoforms of the human “chymotrypsin-like
elastase”.
Elastase-1 is highly stable in feces for up to one
week at room temperature, and for one month
when stored at 4°C, thus making conservation
simpler. The only caution is that the measurement
must be performed on solid stools; liquid stool
indeed can be associated with false-positive result.
Interpretation of fecal elastase-1 test is shown in
figure 1. The sensitivity of FE-1 for mild, moderate,
and severe EPI patients is 63 percent, 100 percent,
and 100 percent, respectively and the specificity
for EPI is 93 percent (5) hence it is a useful tool for
diagnosing EPI.

Figure 1: Interpretation of Fecal Elastase-1 test:
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Edward Syndrome: Rare Autosomal Aneuploidy
Ms Anum Fatima
Molecular Pathology

Introduction
Edward’s Syndrome is also known as Trisomy 18
(47, XX or XY,+18) is a genetic disorder caused
by the presence of all or part of an extra 18th
chromosome. Trisomy 18 was first described by John
H. Edwards in 1960. The Incidence is one in 6000
to 8000 live births. It is more common in females,
with a male-to-females ratio of 1:3-4. The risk of
trisomy also increase with maternal age. Individuals
with trisomy 18 often have slow growth before birth
(intrauterine growth retardation) and a low birth
weight.
Due to the presence of several life-threatening
medical problems, many individuals with trisomy 18
die before birth or within their first month. Trisomy
18 is the second most common autosomal trisomy
after Down Syndrome Trisomy 21. Cytogenetic
Studies of Human oocytes and sperm reveals that
more than 90 percent of the abnormalities observed
in oocytes and less than 50 percent of these see in
sperm are numerical. The most common features of
trisomy 18 includes mental and growth deficiencies,
craniofacial dysmorphism, prominent occiput
,narrow bifrontal, small mouth, narrow place, low-set
malformed ears, microganthia, clenced hands with
a tendency for the second fingers or THIRD fingers
or polydactyl, rocker bottom feet, shortage sternum,
cardiac anomalies ( VSD,ASD and PDA).

Clenched Hand

Rocker-Bottom feet

Life Expectancy
Currently studies showed that medico survival
average of trisomy 18 is approximately two to
22

five days and one week survival rates is 35-45
percent. Some studies also reports survival up to
14.5 Days (Carter et.al). Approximately five to
ten-percent of children with Edward’s syndrome
survive beyond their first year of life, requiring
treatments that are appropriate for the various
and chronic effects that are associated with the
syndrome. Mosaic Trisomy 18 is reported in
some cases and found associated with normal
intelligence and long term survival (Beratis
et.al, Collins et.al). Edward’s syndrome may be
detected prior to the birth of the child. Potential
testing includes maternal serum alpha-fetal
protein analysis or screening, amniocentesis,
ultrasonography, and chorionic villus sampling.
Molecular Cytogenetic Studies
Molecular Studies performed on a total of 10 patient
with Partial MT 18, suggest that the region proximal
to band 18q12 does not contribute to the Syndrome,
whereas Two clinical response, one proximal (18
q12.1---q 22) and one distal (18 q 22.3----qter)
could work in co-operation to provide the typical
trisomy 18 Phenotype (Kline et.al and Mewar et.al).
In addition, severe mental retardation in these patient
could be associated with trisomy of the reason 18q
12.3-------q21.1.

Trisomy 18

Chromosome 18

It is very rare syndrome and a protocol for reporting
this critical condition is followed. In case of
positive findings patient’s physician is informed and
consulted for patient’s condition.
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Sirolimus in Renal Transplant
Dr Bilal Hashmi and Ms Maria Masood
Clinical Chemistry

Sirolimus, a hydrophobic macrolide compound
is derived from antinomycete, Streptomyces
hygroscopicus. It is a potent immunosuppressant
(suppression of T- and B-cell proliferation)
selectively blocking the transcriptional activation
of cytokines thus inhibiting cytokine production. It
becomes active when bound to immunophilins. It
also acts as an antimicrobial, antifungal agent.

Table 1: Pharmacokinetics of the Sirolimus.

Sirolimus is used to prevent cellular rejection after
organ transplantation, especially renal transplant, heart
allografts and stem cell transplant recipients. It has been
approved for use in combination with cyclosporine
and also it can be used as a substitute of calcineurin
inhibitor. It is advised to use sirolimus in conjunction
with cyclosporine and corticosteroid as it reduces the
incidence of acute rejection in renal transplant patients
without producing overall adverse effects.

Patients taking sirolimus frequently require
screening lipid profile as hypercholesterolemia
has been observed in patients taking sirolimus
during first six months after transplant. At Aga
Khan Clinical laboratory Sirolimus is recently
introduced. Whole blood sample is required for the
Sirolimus test.

Following entry into the cytoplasm, sirolimus binds to
the FK binding protein and presumably modulate the
activity of the mTOR. The mTOR inhibits interleukin
(IL)-2-mediated signal transduction, resulting
in cell-cycle arrest in the G1-S phase. Sirolimus
block the response of T and B cell activation by
cytokines, which prevents cell-cycle progression
and proliferation. Sirolimus available in two form;
liquid solution and tablet both primarily partition in
red blood cells and is metabolized through hepatic
and intestinal microsomal system (CYP3A4). The
pharmacokinetics is defined in Table 1.

Peak Concentration
1-2 hours
Bioavailability
Oral solution (14%), tablets (27% higher)
Volume of
12 L/kg, with 97 percent of the agent
Distribution
being bound to albumin
Metabolism
Cytochrome P450 3A4
Half Life
57-63 hours
Excretion
biliary Feces (mainly)

Sirolimus is a substrates for cytochrome
P450 3A, the co-administration of sirolimus
with cytochrome P450 3A inducers (some
anticonvulsants, rifampin, isoniazid, St. John’s
wort) and with cytochrome P450 3A inhibitors
(such as azole antifungals, non-dihydropyridine
calcium channel blockers, some macrolide
antibiotics, grapefruit) can result in significant
interactions. Toxicity of this drug can lead
to leukopenia, thrombocytopenia, anemia,
hypercholesterolemia, hypertriglyceridemia,
proteinuria, diarrhea, constipation and dyspepsia.
Regular monitoring of sirolimus blood levels is
recommended to avoid these side effects.

Latest Trends in Clinical Laboratory Science
Technology
Dr Sibtain Ahmed
Clinical Chemistry

Medical laboratory science technology has
progressed over the course of last few decades at
a very rapid rate and the lab gurus have projected
the progression to continue developing at a similar

degree. Patient centered health care is now the talk
of the town. This consists of small handheld devices
and desktop equipment that can be used for testing
outside of patient care facilitates, some even in the
23
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comfort of home by the patient himself via home
based health monitoring systems whose data can be
transmitted with a click through smart gadgets to
centers where it is processed; rather than the patient
himself being present at the testing facility leading
to further reduction in expenses. Its high need of
time to enhance our current understanding on these
advancements, especially the following five areas:
A) Point-of-care Testing
Point of care testing (POCT) is medical testing that
is performed outside of a laboratory setting. POCT
testing commonly referred to as bedside testing or
near-patient testing. It enables medical staff to make
rapid triage and treatment decisions when diagnosing
a patient’s condition or monitoring a treatment
response. With the current advances in POCT testing,
alongside the provision of expanding menu of tests,
devices can transmit results wirelessly and in realtime to the patients’ electronic medical record. Some
systems have been updated with features designed
to assess real time quality control and achieving
regulatory compliance.
B) Automation
Since the advent of the continuous flow analyzer
in the 1950s, laboratory automation has continued
to evolve and expand its capabilities to become
inevitable for the survival of any clinical
laboratory. From a broader perspective, a laboratory
automation system consists of robots, conveyor
systems, machine vision, and computer hardware
and software. Modern automated systems have
significantly improved the throughput from preanalytical right to the post-analytical phase.
C) Self-Monitoring with Wearable Sensors
With an alarming increase globally in the number
of elderly population with numerous health issues,
home based self-monitoring is on the rise keeping
in mind the comfort and ease of care alongside
major cost cutting, as opposed to costly health care
facilities that are at times may be considerably
distant. The current era of modern smart technology
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with wearable sensor based devices have greatly
assisted this cause, as they can monitor and record
real-time data on from the individuals body and then
with connectivity to central lab via smart phones can
log and archive it in the central health records. Such
devices are now being worked into smart bands,
attire, and can even be fastened in the forms of light
belts to the body. For current and future medical
laboratory scientists it is necessary to explore
broader horizons in this context and lining up with
smart technology is inevitable for the advancement
of clinical laboratories.
D) Rapid Specimen Transportation
As specimen transport has seen various
developments in the past few years from conveyer
belts to pneumatic tubes, the use of drone to
transport specimens from distant locations to a
central laboratory as practiced successfully by the
Swiss post in Switzerland has tremendously changed
the game for the laboratories worldwide. Drones
not only add to major cost costing, reduces laborious
task, saves time for the end uses, reduces turnaround
time for the laboratories and helps them expand their
outreach to distant locations.
E) Bio-banks
Bio banks serves as bio repository that stores
human biological samples for its utility in various
clinical aspects like transfusion, transplantation and
research & development. Since the early 90s they
have become an important resource for clinical
laboratories, serving as a major contributor for
present-day research like genomics, biomarker
discovery and individualized medicine. The network
of bio banks in Europe and North America is widely
established and major work is required to be done
from our part of the world to shape in line with the
needs of the time.
Developments in technology will continue to impact
laboratory services; and how we translate them into
practice alongside training & education of future
laboratorians with the ultimate aim of providing a
better patient focused health care.
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Radiology-Neuropathology Correlation
Dr Tamanna Asghari, Dr Sidra Arshad and Dr Shayan Sirat
Histopathology and Radiology

A 20 years old female presented
in the emergency with history of
headache, vomiting and a few
episodes of loss of consciousness.
On detailed investigations, MRI
was performed which showed a
large cystic lesion in right cerebellar
hemisphere with enhancing solid
mural nodule.
Patient underwent craniotomy and
biopsy was sent. Histopathology
examination showed a biphasic
MRI - TIW post contrast axial image (A) and sagittal T2W midline
pattern with variable proportions
image (B): A large cystic lesion in right cerebellar hemisphere with
of compacted bipolar cells with
enhancing solid mural nodule.
Rosenthal fibers and loose, textured
multipolar cells with micro cysts
and occasional granular bodies. No
Ollier’s disease and PHACE syndrome have been
cytological atypia or significant mitosis were seen.
documented.
Final diagnosis of Pilocytic astrocytoma was made
The most common sites of origin are the cerebellum
after radiological –pathological correlation.
and around third ventricle; however, the entire
neuraxis can be afflicted
Discussion
Pilomyxoid astrocytoma a variant is characterized
by uniform bipolar cells in a myxoid background and
Pilocytic astrocytoma (PA) accounts for 5.4
frequent perivascular arrangements
percent of all gliomas and is the most common
glioma in children and adolescents, with no gender
Anaplastic Transformation (Pilocytic Astrocytoma
predilection.
With Anaplasia):
According to WHO classification of CNS tumors
In a subsequent series, anaplasia in pilocytic
(2016) they are classified as WHO grade I tumors,
astrocytoma was found to occur primarily in the
and have a relatively good prognosis.
form of diffuse, brisk mitotic activity (usually > 4
PA is usually sporadic, however, associations
mitoses per 10 high-power fields), with or without
with, Turcot syndrome, neurofibromatosis type 1,
necrosis .

A

B

Immunophenotype
Pilocytic astrocytomas
strongly express GFAP
and S100.
The Ki-67 proliferation
index is low in most cases.
Genetic Profile

Fig A&B show Bipolar cells with Rosenthal fibres, granular bodies and microscystic spaces.

Most of the Pilocytic
astrocytomas harbour
a transforming fusion
25
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gene between KIAA1549 and BRAF gene. This
constitutively activates the MAPK pathway.
Imaging
‘A cystic mass with an enhancing mural nodule’
is the typical manifestation of majority of PAs on
imaging. The pertinent differentials of posterior fossa
pilocytic astrocytoma include: medulloblastoma,
ependymoma, hemangioblastoma, atypical teratoid/
rhabdoid tumor(ATRT) and abscess. The first
two entities are midline tumors and mostly solid;
hemangioblastoma is tumor of adults and occurs
in children when associated with von hipple lindau
disease; ATRT are aggressive looking large solid
masses and abscess have typical clinical presentation.
Fifty percent of the tumors are cystic, with a mural
nodule. Solid component enhances invariably (~95
percent) and the cyst wall enhances in 50 percent of the
cases. Non-necrotic solid tumors are uncommon and
account for only 10 percent of cases. Up to 20 percent
may demonstrate some calcification. Hemorrhage is an
infrequent complication. There is signal loss on T2*/
SWI in case of calcification/hemorrhage.
On diffusion-weighted imaging, the cystic component
of the mass displays the diffusion characteristics of
CSF. The low cellularity of PA is supported by high
apparent diffusion coefficient (ADC) values within the
solid component of the tumor.
Magnetic resonance spectroscopy (MRS) to
evaluate CPA have demonstrated high choline, low
N-acetylaspartate (NAA) and high lactate levels. These
features are usually identified with high grade tumours.

Pilomyxoid astrocytoma (PMA) is a rare variant
of PA. It frequently occurs in the suprasellar/
chiasmatic/hypothalamic region. They are aggressive
grade II tumors and are mainly solid, exhibiting
homogenous or heterogeneous rim enhancement.
PMAs display higher degree of internal haemorrhage,
leptomeningeal spread and expected local recurrence.
No significant differentiating imaging features
have been described in literature for Pilocytic
astrocytoma with anaplasia, however it is thought
to be more solid than cystic. Hence, only histology
can predict the true nature of this disease.
Prognostic and Predictive Factors
l
Overall survival rates at five and ten years
		 are > 95 percent after surgical intervention
		alone
l
Pilocytic astrocytomas of the optic nerve
		 in patients with NF1 seem to have a more
		 indolent behaviour than that of their sporadic
		counterparts.
l
Patient age and extent of resection are key
		prognostic factors

Treatment
The treatment of choice for PA is gross total
resection and is generally curative.
l
In case of residual disease, control of tumor
		 progression can be achieved by re-excision
		 and stereotactic radiosurgery.
l
Pilocytic astrocytoma with anaplastic
		 features warrant radiation therapy and/or
		chemotherapy.
l

		

Nuchal Translucency Scan
Dr Shaista Afzal
Radiology

Nuchal Translucency Scan
NT (Nuchal translucency) is the sonographic
finding in the first trimester due to the subcutaneous
fluid collection behind the fetal neck. The cause
for increased NT thickness includes structural
malformation leading to cardiac failure, disorders
of extracellular matrix and developmental delay or
abnormality of the lymphatic.
26

An association has been reported between the
increased measurement of NT and fetal anomalies,
aneuploidies, genetic disorders, and abortions.
NT scan in the late first trimester in conjunction
with maternal age and serum biomarkers has been
established as an effective method for trisomy
screening . The accuracy of NT scan for detection of
Down syndrome is from 29 percent to 100 percent,
with the false positive rate being 0.3 percent to 11.6
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percent. Early diagnosis can guide through early
management and proper counseling strategy which
can be implemented to lessen the mental trauma of
the expectant parents.
It is important to take gestational age i.e. 11 to 13+6
and crown rump length (CRL) range from 45 to 84
mm into account as NT value is between 50TH and
95th percentile with these values and it increases
with growth of these parameters . The mid sagittal
plane of fetus should be achieved for NT evaluation.
An important factor that affects NT measurement
is the fetal neck position. The measurement can be
decreased by 0.4 mm with fetal neck flexion and
increased by 0.6 mm with extension of fetal neck
flexion. Hence as a standard, for NT measurement
the fetal head should be in a neutral position. The
fetal position in relation to the amniotic membrane
can be a source of error, therefore nuchal edge should
be seen separate from the amniotic membrane .The
correct positioning of calipers i.e. in an “on and on”
position and adequate image magnification with fetus
occupying at least ¾ of the screen size is important
to reduce variability in measurements. At least three
measurements and the mean value of NT should
be obtained for evaluation of risk assessment and
counseling of patients in case of abnormal results.
The competency of the staff enhances the accuracy
and reproducibility of the scan and requires
appropriate training approved by certifying agencies.
Also, for accuracy of measurement there should

be provision of good quality ultrasound machines
with option of multiple frequencies transducers and
availability of transvaginal scanning, especially with
obese patients.
Conclusion
NT evaluation is important in the first trimester as its
increased measurement is associated with a spectrum
of fetal chromosomal and structural abnormalities.
Accurate and reproducible NT measurement requires
strict follow-up of the quality guidelines for the
training, supervision, and technique of the sonologist.

Ultrasound scan in first trimester, CRL of 63 mm corresponding to 12
weeks and five days.
NT measure 1.3mm

Bio-risk Management System in Clinical
Laboratory
Ms Farhat Jahan
Clinical Chemistry

All laboratories are responsible for biosafety and
biosecurity and it is necessary to protect their
workers, population and environment from exposure
or spread any harmful pathogen. This important
function is accomplished by two major actions:
1. No handling of any specified bio-risk in their
facility.
2. By identifying, implementing and maintaining
biosafety and biosecurity measures.
Laboratory biosafety describes the containment
principles and technologies that are need to be

implemented to prevent unintentional exposure to
biological agent or toxins and also to prevent their
accidental release. While laboratory biosecurity
explain the protection, control and accountability for
any biological agent or toxins within laboratory in
order to prevent their misuse, loss or unauthorized
access or intentional unauthorized access.
Bio-risk Management System
The identification of bio-risks Bio-risk management
system includes: biohazard identification,
assessment, management and communication
27
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Biohazard identification, which is identification of
the biological agent, amount and concentration;
bio-risk assessment, which includes the possible
biological risk, susceptible species and health
consequences of an exposure or release from the
facility, available laboratory resources and severity
of harm, potential for theft or misuse; bio-risk
management is a process that requires documentation
of timelines for action, assignment of responsible
persons and completion of reporting; while bio-risk
communication is the interactive and exchange of
information and opinions throughout the risk analysis
process about risk analysis, risk related factors
among the risk communicators or general public/
patients.
The laboratory manager work with bio-risk
management committee to identify which risk
control measure is appropriate and feasible for use in
their laboratory. The bio-risk system consist of four
elements, administrative, operational, engineering
control and personal protective equipment.
Administrative control includes laboratory safety/
security policies, management programs, qualified
trained and competent personnel, training in safe
and secure handling of biological agents and toxins,
health and safety programs, incident and accident
investigation programs, Emergency response and
contingency plans, biological agent and toxin
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inventory management plans, waste management
policies and security policies (i.e. facility security,
visitor or personnel access).
Operational control includes standard operating
procedures for all biosafety and biosecurity processes,
good laboratory safety practices, disinfection and
decontamination practices, specimen and reagent
handling or proper storage practices, fire or other
drills, incident reporting or response procedures.
Engineering Control includes facility ventilation,
biological safety cabinets, physical security which
may include access restrictions, security guards, biometric devices.
Personal protective equipment includes gloves
(hand protection), face mask, N95 respirator, face
shield, hood (face protection), Laboratory coat (body
protection).
The goal is to identify appropriate control measures
for the laboratory, determine if suitable control
measures currently exist in the laboratory, identify
additional control measures that the laboratory
can implement on fiscal resources and available
infrastructure and implement the control measure. It
is an ongoing process in which specific laboratory
bio-risk control measures are regularly monitored.

Estimated Glomerular Filtration Rate (GFR):
A Serum Creatinine-Based Test for the
Detection of Chronic Kidney Disease (CKD)
Dr Siraj Muneer and Mr. Abdul Mateen
Clinical Chemistry

Every day, healthy kidneys filter about 189 liters of
blood and produce about 1.5-2 liters of urine. The
GFR refers to the amount of blood that is filtered
by the glomeruli per minute, and is a measure of
kidney function. As a person’s kidney function
declines due to damage or disease, the GFR
decreases and waste products begin to accumulate
in the blood. GFR values are associated with age,
sex and body surface and are 120 and 130 mL/min
per 1.73 m2 in young men and women, respectively.
Methods of determination of estimated GFR are
shown in Table 1.
28

Chronic kidney disease is associated with a decrease
in kidney function that is often progressive. Early
detection of kidney dysfunction can help to minimize
the damage. This is important as symptoms of
kidney disease may not be noticeable until as much
as 30-40 percent of kidney function is lost. Kidney
function estimation was commonly made using
Serum Creatinine (SCr) concentration, blood urea
nitrogen (BUN) level and urine analysis. However
accumulating evidence has demonstrated that these
biomarkers are not optimal to detect kidney disease
in early stages. Literature have reported GFR to
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Table1: Methods of determination and estimation of GFR and their evaluation
Measuring GFR by clearance of exogenous substances
Inulin (gold standard), iohexol, 51Cr-EDTA, 125I-iothalamate, 99mTCdiethylenetriaaminepentaacetic acid (DTPA)
Measuring GFR by clearance of endogenous substances
Creatinine Clearance (CrCl) = (urine Cr x urine volume)/Serum Cr
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for diagnosis, management,
drug dosing and prognosis,
in addition to its utility for
research and public health.
The KDIGO recommends
that CKD be diagnosed,
classified, and staged by
GFR, shown in Table 2.

Estimated GFR (eGFR)
Creatinine based Schwartz Equation (for children)
eGFR (mL/min/1.73 m2)= 0.413 x [height (cm)/Scr (mg/dL)]

At Aga Khan Clinical
Laboratories, eGFR is
reported using the SCr
Cockcroft Gault Equation
results by CKD-EPI-Pak
eGFR= {([140-age] × weight in kg)/(serum creatinine × 72)} x (0.85 if female)
formula. This formula
MDRD Equation
was first validated on a
186 x (Cr/88.4)-1.154 x (Age)-0.203 x (0.742 if female) x (1.210 if black)
previous performed SCr
CKD-EPI
and results were compared
GFR = 141 x min(Scr/κ,1)α x max(Scr/κ, 1)-1.209 x 0.993Age x 1.018 [if female] x 1.159 [if black]
with the other formulas,
κ is for females and 0.9 for males, α is -0.329 for females and -0.411 for males, min indicates the MDRD, Cockcroft Gault
minimum of SCr/ κ or 1 and max indicates the maximum of SCr/ κ or 1
and CKD-EPI taking
CKD-EPI-Pak
creatinine clearance as the
GFR (ml/min per 1.73 m2) = 0.686 x CKD-EPI 1.059
gold standard (1). Estimated
glomerular filtration rate
Table 2: Stages of Chronic Kidney Disease
is the best test to measure
level of kidney function and
GFR
Description
% of Kidney
Stage
(ml/min/1.73 m2)
Function
determine the stage of kidney
disease. The GFR provides
Kidney damage with normal GFR
90-100%
1
≥90
information regarding
Kidney damage with mild ↓ GFR
60-89%
2
60-89
stage of kidney disease and
Mild to moderate ↓ GFR
45-59%
3A
45-59
helps the doctor plan the
Moderate ↓ GFR
30-44%
3B
30-44
treatment. The earlier kidney
Severe ↓ GFR
15-29%
4
15-29
disease is detected the better
End Stage Renal Disease
<15%
5
<15
the chance of slowing or
be a better marker for assessing kidney function
stopping its progression.
compared to SCr. In clinical practice GFR is crucial
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A Hands on Workshop on ‘Urine Organic
Acids Testing and Interpretation’
Dr Hafsa Majid
Chemical Pathology

Urine organic acid (UOA)
analysis is crucial for
diagnosis of inherited
metabolic disorders, including
the organic acidemias
involving propionic,
methylmalonic, and isovaleric
acidemias, other disorders
such as biotinidase deficiency,
Canavan’s disease, and
certain amino acidopathies
like phenylketonuria and
Tyrosinemia as well. The UOA
chromatograms interpretation
is difficult, diagnosis requires a
certain expertise for accuracy
Picture 1: Facilitator presenting to workshop participants.
as misinterpretation can lead to
The focus of workshop was on understanding of
a wrong diagnosis. It is essential
internal quality control (IQC), proficiency testing
that laboratorians have good understanding
(PT), as well as hands on skills to interpret IQC
of the normal and abnormal patterns of UOA
and PT results and running root cause analysis
chromatogram to reach a diagnosis. To achieve
(RCA) to identify root cause of errors. Workshop
this, Section of Chemical Pathology, Department
started with introduction of all participants
of Pathology and Laboratory Medicine conducted
followed by a pretest quiz via online Kahoot
a half day flipped workshop for consultants and
game to challenge participants’ thinking. This
trainees involved in management of inherited
was followed by lectures covering the basics in
metabolic diseases (IMDs) patients. This workshop
urine organic acid testing, including a talk on
was arranged under the auspices of International
‘An overview of urine organic acids from IMDs
Federation of Clinical Chemistry and Laboratory
perspective’ by Dr Aysha Habib, Section Head
Medicine and Pakistan Society of Chemical
Chemical Pathology. Second talk was on ‘GC-MS
Pathologist on Saturday, March 2nd 2018.

Picture 2: Workshop participants doing group activities.

30

JULY 2019

VOL. 45, ISSUE 2

Picture 3: Group Photo of Workshop organizers and participants.

and Application of Chromatography in Organic
acids Testing’ by Dr. Lena Jafri, director of the
workshop. Last talk of the session was on ‘Correct
Identification of Organic Acids and Metabolites
using the libraries’ by Dr. Hafsa Majid, followed
by an interactive group activity on chromatogram
labelling and interpretation. In the end participants
were given different case studies for diagnosis to
assess their understanding of UOA chromatograms
interpretation.

This workshop was well attended by wide range
of enthusiastic participants including, residents,
technologists and pathologists from different subspecialties of Pathology, from more than five institutes/
laboratories of Karachi. The participants found the
workshop very insightful and comprehensive. They
welcomed these opportunities for more in-depth
understanding of UOA chromatograms labelling and
peer interaction and thanked the organizers for sharing
their rich educational experience.
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The Best of the Past
#Pathologists #Followtheirlead #changeagents
Interview Recorded by
Dr Sidra Arshad

Considering your entire time as a
Histopathologist at Aga Khan University,
can you recall a time (any ‘AHA’ moment) when
you felt most excited about your involvement in
the organization?
Dr Sheema Hasan: A moment in 35 Years, Humm.
Well it cannot be a moment. It was the first few
years when I was really excited. It was the time
when laboratory became functional and we, a small
group of consultants and technologists took the task
of laying the foundation of what later became a
symbol of quality and excellence in the country. We
all worked very hard with one goal in mind that the
histopathology section at AKU evolves as the very
best in the country with an international repute.
After 35 years now I feel proud to see that we have
done it!!
What was your inspiration to become a
histopathologist? Please briefly share your initial
phase of journey i.e. from medical graduate to
consultant.
Dr Sheema Hasan: As a medical graduate or even
in first few years of my career, I never thought of
choosing histopathology as my specialty. I guess the
reason was the lack of exposure to histopathology
or clinical laboratory, in a broader sense, during
the days of medical school. I chose Gynecology/
Obstetrics as an intern and later did three years of
training in medicine. After my marriage I moved
to London, but the job opportunities to practice
Medicine were less there. Therefore, I moved to
Plymouth where I lived alone and started practicing
Medicine. It was then that I decided to choose
some other field as I had to move back to London
to join my family. I applied for pathology residency
in Kingston Hospital, affiliated with Kings College
and was selected. During residency I developed
interest in histopathology and cytopathology. It
was the gold standard in diagnostics, and I liked
the work environment of histology section of the
institute. Since then I never looked back and never
regretted the choice that I made.
Share your one moment when you felt most
proud as a histopathologist.
32

Dr Sheema Hasan:
There were innumerable
moments when I felt really
satisfied. Throughout our
carriers second opinions
are sought on our cases.
These may be reviewed
by other national or
international pathology
centers. So early in my
carrier there was a case on
which the reviewed report
had a different diagnosis
and the patient family was very angry. I felt very
low at that time, but few months’ later patient had
a recurrence at the same site and second biopsy had
features similar to the diagnosis that I rendered on
the first biopsy.
As the senior most histopathologist of the
country, please share your experience of
development of Histopathology field in Pakistan.
Dr Sheema Hasan: In those days the
histopathology was practiced in isolation
as individuals and there was no concept of
intradepartmental or inter consultation or
clinicopathlogical sessions. We pioneered the
practice of group discussions and interacted
with colleagues through interdepartmental and
departmental conferences (DCC) and with
clinicians’ (Clinicopathological conferences
& tumor board meetings), thus building up
long lasting relationships and trust between the
pathologists and clinicians. We started participating
in international forums and started national
presentations and workshops. We also started
structured residency program in all specialties
of Pathology. Now when I look around it gives
us great pleasure to see our trainees’ working as
established and renowned consultant within the
country and abroad.
Any advice for young histopathologist?
Dr Sheema Hasan: There are many shortcuts to
failure but there are no shortcuts to true success.
Through hard work and discipline one can
accomplish anything.
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AKU histopathology faculty participated in Joint 9th Annual conference of ‘Histopathology& Cytology Society of
Pakistan(HCSP)’and 6th Annual conference of ‘International Academy of Pathology (IAP)-Pakistan Division held at
Marriott’s Islamabad from April 20-21, 2019. It is a forum that brings together histopathologists and trainee nationwide.
The scientific program included talks from well renowned International speakers including Prof Emad Rakha from
University of Nottingham, UK, an authoritative figure in the field of Breast Pathology among others

Group picture of the participants and organizers of a multidisciplinary conference on ‘Newborn screening for inherited
metabolic disorders in Pakistan’ in line with world rare day
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Group picture of the participants and organizers of “Coagulation and Haemostasis workshop” conducted at the annual
conference of Pakistan Society of Haematology

Pakistan Journal of Radiology(PJR) celebration of continuous 10 years of publishing with legendry Dr Rashid AhmedTamgha-e-Imtiaz 2017; patron-in-chief of PJR [Right] and Dr Syed Mahmood-Dean faculty of Radiology CPSP [left]
34
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Meeting of Global Mycetoma working Group at NNN (Neglected tropical diseases NGO Network) in September 2018 at
Addis Ababa, Ethiopia
Participants: Briana Reeves and Karlyn D Beer (CDC\DDID\NCEZID), Alexendar Tiendrebeoge, Kingsley Bampoe
Danieal Arggaw, Ashok Moloo (WHO), Afia Zafar and Mohammad Zeeshan (AKUH)

First Molecular Cytogenetic workshop conducted by AKU Molecular pathology faculty at AFIP, Rawalpindi, Pakistan
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